Literature DB >> 21054779

Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke.

E Hanson1, K Jood, S Karlsson, S Nilsson, C Blomstrand, C Jern.   

Abstract

BACKGROUND: Compared with coronary artery disease, there are few studies on von Willebrand factor (VWF) in ischemic stroke (IS). Moreover, there is little information on VWF in the etiologic subtypes of IS.
OBJECTIVES: The aim of the present study was to investigate VWF in IS and in the etiologic subtypes of IS. PATIENTS/
METHODS: The Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS) is a case-control study comprising 600 patients and 600 matched controls. Etiologic IS subtype was defined according to the TOAST criteria. Blood sampling was performed in the acute phase and after 3 months.
RESULTS: The levels of VWF were increased in overall IS, at both time-points. The 3-month VWF levels were increased in the subtypes of large-vessel disease (LVD), cardioembolic (CE) stroke and cryptogenic stroke, but not in the subtype of small-vessel disease (SVD), as compared with the controls. The acute phase VWF levels were significantly increased in all four subtypes. In the multivariate regression analysis, with vascular risk factors as covariates, the 3-month VWF levels were associated with CE stroke and cryptogenic stroke, and the acute phase VWF levels with all subtypes. There were significant subtype-specific differences in VWF, with the highest levels in LVD and CE stroke.
CONCLUSIONS: The present results show that VWF levels are increased in patients with IS. Furthermore, the VWF levels differ between etiologic IS subtypes and thus, it is important to consider etiologic subtypes in future studies of VWF in patients with IS.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21054779     DOI: 10.1111/j.1538-7836.2010.04134.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

1.  Clinical role of von Willebrand factor in acute ischemic stroke.

Authors:  Marija Menih; Miljenko Križmarić; Tanja Hojs Fabjan
Journal:  Wien Klin Wochenschr       Date:  2017-04-13       Impact factor: 1.704

2.  Circulating but not immobilized N-deglycosylated von Willebrand factor increases platelet adhesion under flow conditions.

Authors:  M A Fallah; V Huck; V Niemeyer; A Desch; J I Angerer; T A J McKinnon; A Wixforth; S W Schneider; M F Schneider
Journal:  Biomicrofluidics       Date:  2013-08-26       Impact factor: 2.800

Review 3.  Potential serum biomarkers in the pathophysiological processes of stroke.

Authors:  Yanying Miao; James K Liao
Journal:  Expert Rev Neurother       Date:  2014-01-13       Impact factor: 4.618

Review 4.  von Willebrand factor: an emerging target in stroke therapy.

Authors:  Simon F De Meyer; Guido Stoll; Denisa D Wagner; Christoph Kleinschnitz
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

5.  The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

Authors:  Ahmad H Mufti; Kenichi Ogiwara; Laura L Swystun; Jeroen C J Eikenboom; Ulrich Budde; Wilma M Hopman; Christer Halldén; Jenny Goudemand; Ian R Peake; Anne C Goodeve; David Lillicrap; Daniel J Hampshire
Journal:  Blood Adv       Date:  2018-07-10

6.  Biomarker panels in ischemic stroke.

Authors:  Glen C Jickling; Frank R Sharp
Journal:  Stroke       Date:  2015-02-05       Impact factor: 7.914

7.  Interaction between vWF levels and aspirin resistance in ischemic stroke patients.

Authors:  Yıldız Arslan; Tahir Kurtuluş Yoldaş; Yaşar Zorlu
Journal:  Transl Stroke Res       Date:  2013-04-25       Impact factor: 6.829

8.  The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.

Authors:  Shu-Jin Wang; Zhong-Sen Qu; Qing-De Zhang; Liang Li; Feng Wang; Bin Zhang; Bang-Li Wu; Yu-Wu Zhao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  Population-based study of blood biomarkers in prediction of subacute recurrent stroke.

Authors:  Helen C Segal; Annette I Burgess; Debbie L Poole; Ziyah Mehta; Louise E Silver; Peter M Rothwell
Journal:  Stroke       Date:  2014-08-26       Impact factor: 7.914

10.  von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.

Authors:  Stephen J X Murphy; Soon Tjin Lim; Fionnuala Hickey; Justin A Kinsella; Deirdre R Smith; Sean Tierney; Bridget Egan; T Martin Feeley; Sinéad M Murphy; D Rónán Collins; Tara Coughlan; Desmond O'Neill; Joseph A Harbison; Prakash Madhavan; Sean M O'Neill; Mary-Paula Colgan; James S O'Donnell; Jamie M O'Sullivan; George Hamilton; Dominick J H McCabe
Journal:  Thromb Haemost       Date:  2020-09-15       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.